| Literature DB >> 19036129 |
Sang-Man Jin1, Hyun Ju Lee, Eun-Ah Park, Ho Yun Lee, Sang-Min Lee, Seok-Chul Yang, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Jae-Joon Yim.
Abstract
BACKGROUND: Miliary pulmonary nodules are commonly caused by various infections and cancers. We sought to identify the relative frequencies of various aetiologies and the clinical and radiographic predictors of miliary tuberculosis (TB) in patients with miliary pulmonary nodules.Entities:
Mesh:
Year: 2008 PMID: 19036129 PMCID: PMC2613900 DOI: 10.1186/1471-2334-8-160
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical characteristics of 76 patients with miliary nodules.
| Age (yr), median (range) | 52 (21–86) |
| Male | 38 (50%) |
| Body mass index (kg/m2), mean ± SD | 21.8 ± 3.0* |
| Smoking history | |
| Current smoker | 12/74 (16%) |
| Ex-smoker | 3/74 (4%) |
| Median pack-years (range) | 30 (3–50) |
| Body temperature > 37.8°C | 21/61 (34%) |
| Leukocytosis (>10,000/mm3) | 11/72 (15%) |
| C-reactive protein (mg/dL), mean ± SD | 4.9 ± 5.6† |
| Previous or current malignancy | 18 (24%) |
| Solid organ cancer | 12 |
| Hematologic malignancy | 6 |
| History of previous TB | 5 (7%) |
| Comorbidities | |
| Diabetes mellitus | 2 (3%) |
| HIV infection | 7 (9%) |
| Corticosteroid use‡ | 9 (12%) |
| Connective tissue disease | 6 (8%) |
| Solid organ transplantation | 2 (3%) |
| Chronic kidney disease§ | 2 (3%) |
* Result of 61 subjects
† Result of 55 subjects
‡ Prednisolone equivalent ≥5 mg/d for >3 wk.
§Glomerular filtration rate <60 mL/min/1.73 m2 for 3 or more months.
Etiologies of 76 patients with miliary nodules.
| Tuberculosis | 41 (54%) |
| Disseminated candidiasis | 3 (4%) |
| Malignancy | 20 (26%) |
| Lung cancer* | 7 |
| Breast cancer | 5 |
| Thyroid cancer | 2 |
| Others† | 6 |
| Pneumocconiosis | 6 (8%) |
| Sarcoidosis | 4 (5%) |
| Hypersensitivity pneumonitis | 2 (3%) |
*Six of them had adenocarcinoma of non-bronchioloalveolar carcinoma histology and the other had bronchioloalveolar carcinoma.
†Advanced gastric cancer (1 patient), prostate cancer (1 patient), non-Hodgkin's lymphoma (1 patient), pancreas cancer (1 patient), parotid gland adenoid cystic carcinoma (1 patient), thymic carcinoma (1 patient)
Univariate analysis of clinical characteristics between patients with miliary tuberculosis and other diseases
| TB (n = 41) | Other diseases (n = 35) | ||
| Age ≤30 | 10 (24%) | 1 (3%) | .008 |
| Male | 22 (54%) | 16 (46%) | .490 |
| Body mass index (kg/m2), mean | 20.6 ± 3.2 (n = 32) | 23.1 ± 2.2 (n = 29) | .001 |
| Ever-smoking | 5/40 (13%) | 10/34 (29%) | .197 |
| Body temperature > 37.7°C | 19/39 (49%) | 2/22 (9%) | .002 |
| Leukocytosis | 6/40 (15%) | 5/32 (16%) | 1.000 |
| C-reactive protein (mg/dL) | 5.9 ± 4.8 (n = 35) | 3.1 ± 6.5 (n = 20) | .070 |
| Presence of classic risk factor for miliary TB* | |||
| History of malignancy | 2 (5%) | 16 (46%) | <.001 |
| Solid organ cancer | 0 | 12 (34%) | <.001 |
| Hematologic malignancy | 2 (5%) | 4 (11%) | .405 |
| History of previous TB | 4 (10%) | 1 (3%) | .366 |
| Diabetes mellitus | 2 (5%) | 0 | .496 |
| HIV infection | 7 (17%) | 0 | .013 |
| Corticosteroid use† | 9 (22%) | 0 | .003 |
| Connective tissue disease | 6 (15%) | 0 | .028 |
| Solid organ transplantation | 2 (5%) | 0 | .496 |
| Chronic kidney disease‡ | 2 (5%) | 0 | .496 |
*There could be more than one risk factor.
†Prednisolone equivalent ≥5 mg/d for >3 wk.
‡Glomerular filtration rate <60 mL/min/1.73 m2 for 3 or more months.
Univariate analysis of radiographic characteristics between patients with miliary tuberculosis and other diseases
| TB (n = 41) | Other diseases (n = 35) | ||
| Homogeneous nodule size* | 30 (73%) | 17 (49%) | .028 |
| Dominant distribution | |||
| Random | 37 (90%) | 30 (86%) | .794 |
| Centrilobular | 2 (5%) | 2 (6%)† | |
| Perilymphatic | 2 (5%) | 3 (9%)‡ | |
| Profusion (N/cm2) | |||
| Upper | 5.2 ± 2.7 | 3.2 ± 2.6 | .002 |
| Middle | 5.2 ± 2.6 | 3.1 ± 2.5 | .001 |
| Lower | 4.6 ± 2.5 | 2.5 ± 2.5 | .001 |
| Overall | 5.0 ± 2.4 | 2.9 ± 2.3 | <.001 |
| Sharp margin | 30 (75%) | 20 (57%) | .102 |
| Bronchogenic spread of lesion | 23 (56%) | 5 (14%) | <.001 |
| Ground-glass opacity extent | |||
| None | 20 (49%) | 24 (69%) | .082 |
| 0–25% | 11 (27%) | 10 (29%) | .866 |
| 25–100% | 10 (24%) | 1 (3%) | .008 |
| Preexisting TB lesion | 5 (12%) | 5 (14%) | 1.000 |
| Pleural effusion | 15 (37%) | 10 (29%) | .459 |
| Mediastinal lymphadenopathy | 16 (39%) | 20 (57%) | .115 |
| Consolidation | 17 (42%) | 16 (46%) | .709 |
*Size of all micronodules confined to 0–4 mm
†Peumocconiosis (n = 1), hypersensitivity pneumonia (n = 1)
‡Sarcoidosis (n = 2), pneumoconiosis (n = 1)
Multivariate analysis to identify the clinical and radiographic predictors of miliary TB
| Adjusted OR* (95% CI†) | ||
| Bronchogenic spread of lesion | 9.1 (2.1–50.8) | .002 |
| Ground-glass opacity extent >25% | 13.3 (2.3–146.1) | .003 |
| Age ≤30 | 21.2 (2.7–373.2) | .003 |
| History of malignancy | 0.1 (0.0–0.7) | .013 |
| Corticosteroid use | 20.0 (1.6–2893.8) | .017 |
| HIV infection | 19.9 (1.5–2885.3) | .020 |
*Penalized maximum likelihood
†Profile penalized likelihood confidence interval
‡Penalized likelihood ratio test